Nuvectis Pharma Current Ratio vs. Return On Asset

NVCT Stock  USD 4.65  0.07  1.53%   
Based on the key profitability measurements obtained from Nuvectis Pharma's financial statements, Nuvectis Pharma may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Nuvectis Pharma's ability to earn profits and add value for shareholders.
For Nuvectis Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Nuvectis Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Nuvectis Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Nuvectis Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Nuvectis Pharma over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
For more information on how to buy Nuvectis Stock please use our How to Invest in Nuvectis Pharma guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvectis Pharma. If investors know Nuvectis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvectis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.16)
Return On Assets
(0.61)
Return On Equity
(1.40)
The market value of Nuvectis Pharma is measured differently than its book value, which is the value of Nuvectis that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvectis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Nuvectis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvectis Pharma's market value can be influenced by many factors that don't directly affect Nuvectis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvectis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvectis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvectis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Nuvectis Pharma Return On Asset vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Nuvectis Pharma's current stock value. Our valuation model uses many indicators to compare Nuvectis Pharma value to that of its competitors to determine the firm's financial worth.
Nuvectis Pharma is rated below average in current ratio category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Nuvectis Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Nuvectis Return On Asset vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Nuvectis Pharma

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
5.20 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Nuvectis Pharma

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.61
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Nuvectis Return On Asset Comparison

Nuvectis Pharma is currently under evaluation in return on asset category among its peers.

Nuvectis Pharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Nuvectis Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Nuvectis Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Nuvectis Pharma's change in net profit over the period of time. It can combine multiple indicators of Nuvectis Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company was incorporated in 2020 and is based in Fort Lee, New Jersey. Nuvectis Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.

Nuvectis Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Nuvectis Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Nuvectis Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Nuvectis Pharma's important profitability drivers and their relationship over time.

Use Nuvectis Pharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nuvectis Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nuvectis Pharma will appreciate offsetting losses from the drop in the long position's value.

Nuvectis Pharma Pair Trading

Nuvectis Pharma Pair Trading Analysis

The ability to find closely correlated positions to Nuvectis Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nuvectis Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nuvectis Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nuvectis Pharma to buy it.
The correlation of Nuvectis Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nuvectis Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nuvectis Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nuvectis Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Nuvectis Pharma position

In addition to having Nuvectis Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Banking Thematic Idea Now

Banking
Banking Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Banking theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banking Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Nuvectis Stock Analysis

When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.